Ask AI
ProCE Banner Activity

Evidence-Based Care in Atopic Dermatitis: IL-13 Inhibitors to Treat Moderate to Severe Disease

Podcast Episodes

In this episode, dermatology experts discuss the current evidence for using IL-13 inhibitors for moderate to severe atopic dermatitis, with key take-home points illustrated through a detailed patient case.

Released: June 25, 2025

Expiration: June 24, 2026

Review Activity

Share

Provided by

Provided by Clinical Care Options, LLC in partnership with Practicing Clinicians Exchange, LLC and the National Eczema Association.

ProCE Banner

Supporters

This activity is supported by an educational grant from Lilly.

Lilly

Partners

National Eczema Association

ProCE Banner

Practicing Clinicians Exchange, LLC

ProCE Banner

Disclosure

Primary Author

Andrew F. Alexis, MD, MPH: researcher (funds paid to institution): AbbVie, Amgen, Arcutis, Castle, Dermavant, Galderma, Incyte, Leo.

Daniel Butler, MD: consultant/advisor/speaker: Galderma, Leo, Sanofi.

Shawn G. Kwatra, MD, has no relevant financial relationships to disclose.